Will Dasatinib be included in medical insurance in 2026?

In the field of domestic hematological tumor treatment, whether dasatinib is included in medical insurance has always been a matter of great concern to patients. To be clear, dasatinib is an original targeted drug that has been approved for marketing in China and has been included in the National Reimbursement Directory. However, its reimbursement scope is not "unlimited coverage" but is targeted at patient groups that meet specific indications and medication conditions.

From the perspective of medical insurance policy design, dasatinib is mainly used for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), which is consistent with its core indications approved overseas. For patients who meet the diagnostic criteria and are evaluated by doctors as suitable for dasatinib, they can enjoy a certain proportion of cost reimbursement in accordance with medical insurance policies under standardized prescription and medical insurance review processes. This significantly reduces the long-term financial burden of medication on patients to a certain extent.

However, medical insurance reimbursement is not the same as“zero out-of-pocket payment”. Different regions may have differences in medical insurance implementation details, deductibles, reimbursement ratios, and medication management. Therefore, patients usually need to confirm specific policies with the local medical insurance department or hospital before actually using medication. Overseas experience shows that the accessibility of targeted drugs not only depends on whether the drug is on the market, but is also closely related to the payment system. China's inclusion of dasatinib in medical insurance is considered an important manifestation of the gradual improvement of the blood cancer treatment security system.

In the real world, the medical insurance coverage of dasatinib enables more patients to take the drug regularly for a long time, which is particularly critical for a disease like chronic myelogenous leukemia that requires long-term management. The overseas medical community generally believes that continuous and stable targeted therapy is an important basis for achieving good disease control.

Generally speaking, dasatinib has entered the domestic medical insurance system, providing relatively stable medication protection for eligible patients, but the specific reimbursement situation still needs to be confirmed based on the actual situation of the individual.

Reference materials:https://www.sprycel.com/treatment-for-adults